Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Study confirms PET (positron emission tomography) better than CT (computed tomography) in lung cancer staging

This article was originally published in Clinica

Executive Summary

A Dutch study has provided further evidence that positron emission tomography (PET) is more accurate than computed tomography (CT) in the preoperative staging of non-small cell lung cancer (NSCLC). A report of the study in The New England Journal of Medicine (July 27) says that the sensitivity and specificity of PET using 18F-fluorodeoxyglucose in the detection of mediastinal metastases were 91% and 86% respectively, while the corresponding values for CT were 75% and 66%.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT076895

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel